secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001558370-25-002842
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Coherus stockholders approve UDENYCA sale to Intas Pharmaceuticals
------------------------------------------------------------------

- Stockholders voted 70,989,067 FOR, 968,989 AGAINST, 621,431 ABSTAIN; majority threshold was 57,945,094.
- Approval clears key milestone for divestiture of UDENYCA (pegfilgrastim-cbqv) franchise under Dec 2, 2024 Asset Purchase Agreement.
- Special Meeting held virtually on March 11, 2025; 115,890,186 shares outstanding as of Jan 27, 2025 record date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025002842/0001558370-25-002842-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025002842/chrs-20250311x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-002842

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer